Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
{{output}}
In a multicenter, randomized, double-blind trial, the authors compared the antihypertensive efficacy of once-daily treatment with the new angiotensin II type 1 receptor blocker (ARB) olmesartan (20 mg) with recommended starting doses of losartan (50 mg), valsa... ...
